Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations Results From the COBIS (Coronary Bifurcation Stenting) Registry
- Authors
- Bin Song, Young; Hahn, Joo-Yong; Choi, Seung-Hyuk; Choi, Jin-Ho; Lee, Sang Hoon; Jeong, Myung-Ho; Kim, Hyo-Soo; Seong, In-Whan; Yang, Ju-Young; Rha, Seung Woon; Jang, Yangsoo; Yoon, Jung Han; Tahk, Seung-Jea; Seung, Ki Bae; Park, Seung-Jung; Gwon, Hyeon-Cheol
- Issue Date
- 20-4월-2010
- Publisher
- ELSEVIER SCIENCE INC
- Keywords
- angioplasty; bifurcation lesions; paclitaxel-eluting stent; sirolimus-eluting stent
- Citation
- JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, v.55, no.16, pp.1742 - 1749
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Volume
- 55
- Number
- 16
- Start Page
- 1742
- End Page
- 1749
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/116623
- DOI
- 10.1016/j.jacc.2010.02.008
- ISSN
- 0735-1097
- Abstract
- Objectives We aimed to compare the long-term clinical outcomes of patients treated with sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES) for coronary bifurcation lesions. Background There are limited data regarding comparisons of SES and PES for the treatment of bifurcation lesions. Methods Patients who received percutaneous coronary intervention for non-left main bifurcation lesions were enrolled from 16 centers in Korea between January 2004 and June 2006. We compared major adverse cardiac events (MACE [cardiac death, myocardial infarction, or target lesion revascularization]) between the SES and PES groups in patients overall and in 407 patient pairs generated by propensity-score matching. Results We evaluated 1,033 patients with bifurcation lesions treated with SES and 562 patients treated with PES. The median follow-up duration was 22 months. Treatment with SES was associated with a lower incidence of MACE (hazard ratio [HR]: 0.53, 95% confidence interval [CI]: 0.32 to 0.89, p < 0.01) and target lesion revascularization (HR: 0.55, 95% CI: 0.31 to 0.97, p = 0.02), but not of cardiac death (HR: 2.77, 95% CI: 0.40 to 18.99, p = 0.62) and cardiac death or myocardial infarction (HR: 0.97, 95% CI: 0.38 to 2.49, p = 0.94). After propensity-score matching, patients with SES still had fewer MACE and target lesion revascularization incidences than did patients with PES (HR: 0.52, 95% CI: 0.30 to 0.91, p = 0.02, and HR: 0.48, 95% CI: 0.25 to 0.91, p = 0.02, respectively). There was no significant difference in the occurrences of stent thrombosis between the groups (0.7% vs. 0.7%, p = 0.94). Conclusions In patients with bifurcation lesions, the use of SES resulted in better long-term outcomes than did the use of PES, primarily by decreasing the rate of repeat revascularization. (Coronary Bifurcation Stenting Registry in South Korea [COBIS]; NCT00851526) (J Am Coll Cardiol 2010;55:1743-50) c 2010 by the American College of Cardiology Foundation
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.